Bristol Myers Squibb : Gets European Union Approval for MS Drug Zeposia

By Colin Kellaher

Bristol-Myers Squibb Co. on Wednesday said the European Commission approved Zeposia for the treatment of adults with relapsing remitting multiple sclerosis with active disease.

The New York biopharmaceutical company said Zeposia, an oral once-daily medication, becomes the only EC-approved sphingosine-1-phosphate receptor modulator for such patients with active disease.

Bristol-Myers, which in March received U.S. Food and Drug Administration for Zeposia for adults with relapsing forms of multiple sclerosis, is also developing the drug for additional immune-inflammatory indications, including ulcerative colitis and Crohn's disease.

Write to Colin Kellaher at [e-mail]